agoniste glp 1 GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes GLP-1 Agonists - What is

What are blood clots or TEV

Its about how medications are reaching patients in the first place

There are many drivers of this growth, including: The appeal of increased drug efficacy Improved side effect profile Greater obesity and diabetes prevalence Additional indications (e.g., heart, kidney, and liver health) Social media Cultural shifts toward greater acceptance of obesity as a disease Over 12% of the U.S

Gastrointestinal effects are the most frequently reported side effects, classified as 'very common' (affecting more than 1 in 10 people) in the SmPCs for both Wegovy and Saxenda

GLP-1 therapy can counter menopause-related metabolic slowdown and unhealthy visceral fat gain

That difference explains why weight expectations differ